What is tirzepatide?
Tirzepatide activates two gut-hormone receptors at once — GLP-1 and GIP — which is why researchers call it a dual agonist and why it has drawn so much attention in weight and metabolic research.
This page collects everything we've written about it: how it works, dosing and titration, side effects, comparisons with semaglutide, and what compounded tirzepatide involves. Compounded tirzepatide is available only by prescription; a licensed provider reviews every request, and not everyone qualifies. Start with the mechanism article if you're new — the rest builds on it.
100 articles on this topic
-
Tirzepatide Plateau: Why Weight Loss Slows
A tirzepatide plateau is usually the point where a smaller body and stronger biological pressure to maintain weight balance the medication's effects. A brief stall is not the same thing, and a prescriber should review the pattern before changing treatment.
-
Tirzepatide and Birth Control: The 4-Week Rule
Tirzepatide may reduce the absorption of birth control taken by mouth. The current U.S. labels advise non-oral contraception or an added barrier method for four weeks after starting and after every dose increase.
-
Tirzepatide Benefits: What the Trials Show
Tirzepatide benefits are best established for weight reduction and blood-sugar control, with a branded indication for moderate-to-severe sleep apnea in adults with obesity. Heart failure, liver, blood-pressure and lipid findings are promising but narrower.
-
Tirzepatide Constipation: How Long It Lasts
Tirzepatide constipation is common, especially in the first weeks and after dose increases. It often eases as treatment stabilizes, while severe or persistent symptoms need a clinician’s attention.
-
Is Tirzepatide FDA Approved? Not When Compounded
Tirzepatide has branded approvals under Mounjaro and Zepbound. A compounded preparation is different from an FDA-approved product: the formulation offered here is not FDA-approved.
-
Tirzepatide Long-Term Side Effects: 3-Year Data
Three-year weight-management data and four-year cardiovascular data have not revealed a new late safety signal. They also do not tell us what decades of exposure will look like.
-
What Happens When You Stop Taking Tirzepatide?
Appetite suppression fades as tirzepatide clears, and weight regain is common but neither immediate nor inevitable. SURMOUNT-4 shows the difference between stopping and continuing over one year.
-
Are Peptides Legal in the US? What the Law Says
Prescription peptides can be lawful when a licensed provider prescribes them and an authorized pharmacy dispenses them under federal and state rules. A compounded medication, an approved drug and a grey-market vial do not share the same legal status.
-
Tirzepatide for Type 2 Diabetes: Trial Results
Across the SURPASS trials, adults assigned to tirzepatide had average HbA1c reductions of roughly 1.9 to 2.4 percentage points over 40 to 52 weeks. The right comparison depends on a person's existing diabetes treatment and clinical risks.
-
Can You Use HSA for GLP-1? Eligibility Rules
A prescribed GLP-1 may be HSA- or FSA-eligible when it treats a physician-diagnosed condition. The diagnosis, documentation and administrator's rules determine whether a claim is accepted.
-
How Long Does GLP-1 Nausea Last?
A semaglutide nausea episode lasted a median of 8 days in pooled weight-management trials. Symptoms usually cluster around starting treatment and dose increases, then ease as titration settles.
-
Does Tirzepatide Make You Tired? What Trials Say
Fatigue was reported by 5–7% of trial participants on tirzepatide against 3% on placebo. The more useful question is what is actually causing it.
-
Does Insurance Cover Tirzepatide? 2026 Guide
Insurance may cover Mounjaro for type 2 diabetes, while Zepbound coverage for obesity or sleep apnea depends on the plan. Compounded tirzepatide is generally self-pay.
-
How Long Does Tirzepatide Stay in Your System?
Tirzepatide usually takes about 25–30 days to fall to a small fraction of its starting level after the last dose. Its five-to-six-day half-life explains that estimate, but side effects and clinical effects do not end on one exact day.
-
Tirzepatide Diarrhea: How Long It Lasts
Diarrhea is common with tirzepatide, especially after treatment begins or the dose increases. It is usually temporary, but persistent symptoms can cause dehydration and deserve a clinician's attention.
-
Is Tirzepatide Safe? What the Evidence Shows
Safety is not a property of the molecule. It is the dose, the source of the vial, your own medical history, and whether a licensed clinician is accountable for the decision.
-
Tirzepatide vs Retatrutide: How They Compare
Tirzepatide is a dual GIP/GLP-1 agonist with completed phase 3 trials and approved U.S. indications. Retatrutide is an investigational triple agonist that cannot be prescribed here yet — and that, not potency, is the difference that matters.
-
Tirzepatide and Thyroid Cancer: What We Know
The boxed warning comes from thyroid C-cell tumors in rats, not proof of human cancer. Human studies conflict, so MTC and MEN 2 history remains the decisive screening issue.
-
Tirzepatide Weight Loss Results by Month
In SURMOUNT-1, average weight loss reached 15.0% to 20.9% at 72 weeks, depending on dose. The first month was only the initiation phase, and results varied widely.
-
Switching From Semaglutide to Tirzepatide
There is no validated milligram equivalence between the two molecules. Tirzepatide restarts at its own labeled starting dose no matter where the semaglutide dose ended, and a prescriber sets the timing.
Page 4 of 5 · 100 articles